The adhesion G protein-coupled receptors (aGPCRs) are a large yet poorly understood family of seven-transmembrane proteins. A defining characteristic of the aGPCR family is the conserved GAIN domain, which has autoproteolytic activity and can cleave the receptors near the first transmembrane domain. Several aGPCRs, including ADGRB1 (BAI1 or B1) and ADGRG1 (GPR56 or G1), have been found to exhibit significantly increased constitutive activity when truncated to mimic GAIN domain cleavage ($\Delta$NT). Recent reports have suggested that the new N-terminal stalk, which is revealed by GAIN domain cleavage, can directly activate aGPCRs as a tethered agonist. We tested this hypothesis in studies on two distinct aGPCRs, B1 and G1, by engineering mutant receptors lacking the entire NT including the stalk (B1- and G1-SL, with “SL” indicating “stalk-less”). These receptors were evaluated in a battery of signaling assays and compared with full-length wild-type and cleavage-mimicking ($\Delta$NT) forms of the two receptors. We found that B1-SL, in multiple assays, exhibited robust signaling activity, suggesting that the membrane-proximal stalk region is not necessary for its activation. For G1, however, the results were mixed, with the SL mutant exhibiting robust activity in several signaling assays (including TGF-$\alpha$ shedding, activation of NFAT luciferase, and $\beta$-arrestin recruitment) but reduced activity relative to $\Delta$NT in a distinct assay (activation of SRF luciferase). These data support a model in which the activation of certain pathways downstream of aGPCRs is stalk-dependent, whereas signaling to other pathways is stalk-independent.

Despite their essential roles, the aGPCRs are poorly understood, with most members still considered orphan receptors with no known ligands. These receptors are characterized by large, multi-domain N termini that mediate cell-to-cell and cell-to-extracellular matrix interactions. Nearly all aGPCRs have an N-terminal juxtamembrane GPCR Autoproteolysis-Inducing (GAIN) domain, which can cleave the receptor into two non-covalently associated protomers (4). N-terminal cleavage is thought to be a critical activation step because a number of groups have reported that aGPCR truncated mutants that mimic post-cleavage receptors exhibit enhanced constitutive activity; these include BAI1/ADGRB1 (5), BAI2/ADGRB2 (6), GPR133/ADGRD1 (7), CD97/ADGRE5 (8), GPR110/ADGRF1 (9), GPR56/ADGRG1 (9, 10), GPR64/ADGRG2 (11, 12), GPR126/ADGRG6 (13) and VLGR1/ADGRV1 (14). These data prompted the proposal of a disinhibition model of aGPCR activation. In this model, the N-terminal fragment (NTF) inhibits the constitutive signaling ability of the 7TM protomer (also known as the C-terminal fragment or CTF) until the NTF is engaged by a large extracellular ligand, which results in a conformational change and/or removal of the NTF to relieve inhibition and unleash maximal receptor activity (15).

The disinhibition model is a general model that leaves open the mechanistic question of precisely how aGPCR NTF regions inhibit receptor signaling. At least two more mechanistically specific models have been discussed, one in which the NTF acts as a tethered antagonist to suppress signaling by the CTF and another model in which the NTF lacks antagonist activity per se but instead masks a cryptic agonist that becomes unveiled upon cleavage and removal of the NTF (Fig. 1) (2). Several recent reports have provided evidence in support of the cryptic agonist model (7, 9, 11). Liewscher and colleagues found that peptides mimicking the remaining post-cleavage NT stalk (also known as the “stachel”) can activate GPR126/ADGRG6, GPR133/ADGRD1 and GPR64/ADGRG2 (7, 11). Similarly, Stovou et al. demonstrated that GPR110/ADGRF1 and GPR56/ADGRG1 can also be activated by stalk-mimetic peptides (9). These findings have raised the question of whether signaling by all aGPCRs is dependent upon agonistic sequences in the receptor N-terminal stalk regions.

In the studies described here, we performed a series of tests of the cryptic agonist model for two distinct aGPCRs: GPR56/ADGRG1, hereafter referred to as “G1,” and BAI1/ADGRB1, hereafter referred to as “B1.” G1 is one of the most intensively-studied aGPCRs because mutations in this receptor cause a
Role of N-terminal Stalk in aGPCR Activation

FIGURE 1. Tethered Cryptic Agonist Model of Adhesion GPCR Activation. 
A, according to this model, the unstimulated receptor is inactive due to the masking of an agonistic region of the stalk by the NTF. B, following ligand binding to the NTF, the NTF is released from the seven-transmembrane CTF to unveil a new N-terminal stalk, which then stimulates G protein-dependent signaling activity.

brain developmental disorder in humans (16). B1 is also a receptor of great physiological interest because it has been shown to play a critical role in regulating macrophage phagocytosis (17), muscle development (18) and synaptic plasticity in the brain (19–21).

To explore the importance of the stalk regions of these two aGPCRs for receptor signaling, we took two approaches. First, since the cryptic agonist model is largely dependent on GAIN domain cleavage, we engineered a cleavage-deficient form of G1 by mutating the catalytic threonine (Thr-383) to alanine, and additionally assessed signaling by full-length B1, which is naturally cleavage-deficient in HEK cells (4). Second, we created mutant forms of G1 and B1 that lack almost the entire NT, including the stalk region. According to the cryptic agonist model, these deletions should render the receptors completely inactive due to a lack of the tethered agonist that is necessary for receptor activation. Since most if not all GPCRs can couple to multiple downstream pathways that may be differentially activated by distinct receptor active conformations (22), the signaling activities of the G1 and B1 stalkless mutants were assessed in a battery of different assays to provide a panoramic view of the importance of the stalk regions for receptor signaling.

Experimental Procedures

Constructs—Human B1ΔNT (927–1584) and B1-SL (944–1584) were subcloned into pcDNA3.1+ between 5’ EcoRI (B1ΔNT: AGA CCA GAA TTC ATG TCC ACC TTC GCC ATC TTA GGC CAG CTC) or HindIII (B1-SL: AGA CCA AAG CTT ATG GCG ACT CTT CCG TCG GTG ACG CTC) and 3’ XbaI (AGA CCA TCT AGA TCA GAC CCT CTC GTG GAG GTC GAT GTC). Human G1ΔNT (383–693) and G1-SL (404–693) were subcloned into pcDNA3.1 between 5’ HindIII (G1ΔNT: GCA AAG AAG CTT ATG ACC TAC TTT GCA GTG CTG ATG; G1-SL: GCA AAG AAG CTT ATG AGC CTC CTC TCC TCC GTG GG) and 3’ XbaI (GCA AAG TCT AGA CTA GAT GCC GCT GGA CGA GGT).

FLAG-β-arrestin2 was purchased from Addgene, the RGS domain of p115RhoGEF (RGSp115) was a gift from Tohru Kozasa (Univ. of Illinois Chicago), and HA-ubiquitin was kindly provided by Keqiang Ye (Emory University). These constructs have been described previously (5). Internal EE-tagged Gα13 was acquired from the cDNA Resource Center (cdna.org).

Cell Culture—HEK-293T/17 cells were acquired from ATCC (Manassas, VA) and maintained in DMEM (Life Technologies) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin in a humid, 5% CO2, 37 °C incubator. Cells were transfected using Mirus (Madison, WI) TransIT-LT1 according to the manufacturer’s protocol.

Western Blot—Protein samples were reduced and denatured in Laemmli buffer, loaded into 4–20% Tris-Glycine gels (Bio-Rad) for SDS-PAGE, and then transferred to nitrocellulose membranes (Bio-Rad). Blots were blocked with 5% milk (in 50 mM NaCl, 10 mM HEPES, pH 7.3 with 1% Tween-20 (Sigma)) and incubated with primary antibodies for 1 h at room temperature overnight at 4 °C. The B1 C-terminal antibody was a gift from Dr. Erwin Van Meir and has been described previously (5). The anti-GPR56 C-terminal antibody was developed by Orbigene, Inc. via injection of rabbits with a peptide (CSNDSARLPSGGSSTSSRI) derived from the GPR56 C-terminus, and has been characterized previously (10). The biotinylated anti-GPR56 N-terminal antibody was purchased from R&D Systems. Rat anti-HA (Roche), mouse HRP-conjugated anti-FLAG (Sigma), and mouse anti-Glu Glu (Abcam) antibodies were used to detect epitope-tagged proteins. HRP-conjugated secondary antibodies were purchased from GE Healthcare and antibody labeling of specific bands was visualized using Thermo Scientific SuperSignal West solutions.

Cell Surface Biotinylation—HEK-293T cells were transfected with 2 μg of DNA (empty vector or receptor). At 24-h post-transfection, cells were placed on ice and washed with ice-cold PBS+Ca2+ three times. Cells were then incubated with 10 μM Sulfo-NHS-Biotin (Thermo Scientific) in PBS+Ca2+ on ice for 30 min and then washed three more times with PBS+Ca2+ + 100 mM glycine. Cells were resuspended in 250 μl of lysis buffer (1% Triton X-100, 25 mM HEPES, 150 mM NaCl, 10 mM MgCl2, 1 mM EDTA, protease inhibitor mixture (Roche Diagnostics), and 2% glycerol) and lysed by slowly rotating on a spinning wheel for 30 min at 4 °C. Cell debris was cleared by centrifugation, and soluble cell lysates were incubated with 50 μl of streptavidin agarose beads (Thermo Scientific) for 1 h at 4 °C. Beads were washed three times with lysis buffer and resuspended in 60 μl of Laemmli buffer. Biotinylated proteins were detected via Western blot, as described above.

β-Arrestin Binding Assay—HEK-293T cells were transfected with a total of 6 μg of DNA (empty vector, receptor, FLAG-βAr2 or HA-βArr2). The next day, cells were washed with cold PBS+Ca2+ and lysed by harvest buffer (150 mM NaCl, 25 mM HEPES pH 7.3, 1 mM EDTA, 10 mM MgCl2, 1% Triton X-100, Roche EDTA-free complete protease inhibitor mixture tablet). Lysates were rotated at 4 °C for 45 min to solubilize integral membrane proteins and membranes were cleared by centrifugation (15 min at 17,000 × g, 4 °C). Solubilizes were added to magnetic anti-FLAG beads (Sigma) or anti-HA agarose beads (Sigma) and rotated at 4 °C for 1 h. Beads were
GAIN domain cleavage is not necessary for G1 activity. A, schematic of T383A point mutation in G1. B, G1-T383A is expressed on HEK cell surface, albeit at a reduced level compared with the wild-type receptor. Molecular weight markers (in kDa) are shown on the left side of the blots. C, Western blots of G1 and G1-T383A reveal a ~75 kDa band for G1-T383A that is both N-terminally and C-terminally reactive, suggesting non-cleavage of the mutant receptor. Equal amounts of protein (10–20 μg) were loaded in each lane for the blots shown in panels B and C, and these experiments were performed 3–4 times each. D and E, G1 and G1-T383A produce comparable activity in the AP-TGFα shedding and SRF-luciferase assays. Results for TGFα and SRF-luc are from 3–6 independent experiments (± S.E. shown, * , p < 0.05; ** , p < 0.01; *** , p < 0.001 versus cells transfected with empty vector, denoted by EV).

Results

Cleavage-deficient Receptors Retain Signaling Activity—To test the cryptic agonist model of aGPCR activation, we performed parallel studies on two distinct aGPCRs: GPR56/ADGRG1 (“G1”) and BAII/ADGRB1 (“B1”). According to the cryptic agonist model, signaling activity depends upon efficient GAIN domain cleavage followed by dissociation of the N-terminal fragment (NTF) to unveil the agonistic peptide found on the remaining N-terminal stalk of the 7TM protomer (the C-terminal fragment or CTF). Thus, we tested whether GAIN domain cleavage was indeed necessary for G1 and B1 constitutive activity.

As G1 is efficiently cleaved in transfected HEK-293T cells (10), we introduced a point mutation to the G1 GAIN domain at the site of cleavage (T383A) to create a cleavage-deficient version of the receptor (Fig. 2A). Human G1 mutations (C346S and W349S) that abrogate GAIN domain cleavage have been shown to result in the devastating neurological condition bilateral frontoparietal polymicrogyria, which led to speculation that autoproteolysis may be necessary for proper aGPCR function (24, 25). However, more recent crystallographic studies provided insights as to how GAIN domain cleavage can be abro-
gated without inducing misfolding of the GAIN domain (4). Using a cell surface biotinylation approach, we found that indeed G1-T383A (T383A) traffics to the plasma membrane, albeit at a somewhat reduced level compared with the wild-type receptor (Fig. 2B). To validate whether T383A is indeed cleavage-deficient, we probed for expression of the mutant receptor in Western blots using both C-terminal and N-terminal specific antibodies (Fig. 2C). The left panel of Fig. 2C displays the expression patterns of the wild-type and T383A receptors using a C-terminal specific antibody. For wild-type G1, there is a prominent band at ~45 kDa which represents the monomeric, cleaved 7TM protomer. As expected, the T383A mutant lacks the ~45 kDa band and instead displays a prominent band at ~75 kDa which is the predicted molecular weight of full-length, uncleaved G1. Higher order bands for either the wild-type or T383A receptors are likely to be unresolved, oligomeric complexes. The right-hand panel of Fig. 2C displays the expression patterns of both receptors as detected by an N-terminal specific antibody. Here bands are found at ~70 kDa and ~75 kDa for the wild-type receptor and T383A, respectively. The ~75 kDa band of T383A is both C-terminally and N-terminally reactive, providing strong evidence that the point mutation does indeed abrogate cleavage to result in a single, uncleaved protein.

We next assessed the basal constitutive activity of the T383A mutant using two distinct downstream readouts: TGFα shedding and activation of SRF luciferase. G1 has previously been reported to couple to Gα12/13 (9, 10, 26), and GPCRs that activate Gαα or Gα12/13-mediated pathways stimulate the ectodomain shedding of TGFα from the plasma membrane, with the amount of TGFα released into the conditioned media serving as a proxy for receptor activity (23). We observed that wild-type G1 and the T383A mutant displayed an equal level of activity in the TGFα shedding assay (Fig. 2D). Next, we compared the activities of wild-type G1 and T383A in a serum response factor (SRF)-luciferase reporter assay, another well-described readout for Gα12/13-coupled receptors that has previously been shown to be activated by G1 (27). In agreement with our TGFα shedding data, the T383A mutant mediated an approximately equal level of signaling activity to wild-type G1 in the SRF-luciferase assay (Fig. 2E). Regarding B1, this receptor is not efficiently cleaved in HEK-293T cells, as evidenced by >99% of the protein consistently appearing between 150–250 kDa in Western blots (5). Nonetheless, full-length, uncleaved B1 exhibits substantial constitutive G protein-dependent signaling activity, as shown in previously published studies (5) and also shown below. Taken together, these data provide evidence that GAIN domain cleavage is not necessary for activity, at least for G1 and B1.

**Receptors Lacking the Entire N Terminus Retain Activity in a Battery of Signaling Assays**—It is plausible that an agonistic peptide region of the stalk could still be important for activation of aGPCR signaling even in the absence of GAIN autoproteolysis, as cleavage-independent conformational changes that expose the cryptic agonist could conceivably be responsible for receptor activity. Therefore, to definitively answer the question of whether the stalk does indeed contain a requisite agonist for G1 and B1 signaling, we created mutant versions of the receptors that lack the entire NT (including the stalk) such that they begin very close to the start of the predicted first transmembrane domain (Fig. 3, A and C). These stalkless ("SL") mutant receptors expressed and were trafficked to the plasma membrane at levels comparable to ΔNT versions of G1 and B1 (Fig. 3, B and D), revealing that removal of the stalk region did not result in impairments in receptor expression or trafficking.

It has previously been reported that deletion of the NT up to the site of GAIN cleavage results in significant increases in the constitutive activity of aGPCRs, including G1 and B1 (5, 9, 10). According to the cryptic agonist model, further NT deletions that remove some or all of the stalk region should render the receptors inactive. To assess the activities of G1-SL and B1-SL, we utilized a battery of signaling assays. In the TGFα shedding
assay, G1-SL mediated significant signaling compared with mock-transfected cells (Fig. 4A: main effect of receptor F (3,20) = 19.98, p < 0.0001, post hoc EV versus G1-SL p < 0.0001), with the extent of signaling not significantly different from that mediated by G1ΔNT (p > 0.05). The results were different, though, in the SRF-luciferase assay, in which G1ΔNT exhibited robust activity but G1-SL did not (Fig. 4B: main effect of receptor F (4, 25) = 16.97, p < 0.0001, post hoc EV versus G1-SL p > 0.05). Given these contrasting results, we measured receptor activity using a third signaling output: transcription of the nuclear factor of activated T-cells (NFAT), a readout that is predominantly by heterotrimeric G proteins.

In contrast to G1-SL, which displayed activity in two out of three signaling assays utilized, B1-SL displayed significant signaling activity over mock-transfected cells in all three assays (Fig. 4, D–F). First, we found that B1ΔNT and B1-SL induced significantly more TGFα-shedding than mock-transfected cells (Fig. 4D: main effect of receptor transfection, one-way ANOVA, F (3, 19) = 15.17, post-hoc B1: p > 0.05, B1ΔNT: p < 0.01, B1-SL: p < 0.0001). In the SRF-luciferase assay (4E), one-way ANOVA found a main effect of receptor transfection (F (3, 16) = 11.67, p = 0.0003). Post-hoc comparisons revealed that B1 (p < 0.001), B1ΔNT (p < 0.01) and B1-SL (p < 0.01) all displayed significant activity over empty vector (EV) transfected controls but were not significantly different from each other. However, in measuring NFAT luciferase activity (4F), we again found a main effect of receptor transfection in one-way ANOVA (F (3, 12) = 37.46, p < 0.0001) but found that full-length B1 showed no significant activity over empty vector whereas B1ΔNT (p < 0.001) and B1-SL (p < 0.0001) exhibited robust activity that was highly significant over baseline. In fact, B1-SL was significantly more active than B1ΔNT (p < 0.01).

Similar to our findings with G1, this signaling activity from B1 was significantly inhibited by co-transfection with the RGS domain of p115RhoGEF (Fig. 5C: one-sample t test, B1ΔNT p = 0.0032, B1-SL p = 0.0005 compared with 0.0) and also inhibited by overnight treatment (50 μM) with gallein (Fig. 5D: one-sample t test, B1ΔNT p = 0.0064, B1-SL p = 0.0025 compared with 0.0) demonstrating that this signaling activity is dependent on heterotrimeric G proteins.
Role of N-terminal Stalk in aGPCR Activation

Finally, to further assess the abilities of the SL mutants to couple to heterotrimeric G proteins, we performed co-immunoprecipitation experiments with each receptor and co-transfected EE-tagged Go(13). In these experiments, the tagged G protein was immunoprecipitated and Western blots were performed to detect any co-immunoprecipitated receptor. For both G1 and B1, we found that the truncated ΔNT and SL forms strongly and significantly co-immunoprecipitated with Go(13) but the full-length forms of the receptors did not (Fig. 6A: G1 one-way ANOVA F(2, 6) = 10.49, p < 0.05, post-hoc test versus full-length G1, G1 ΔNT p < 0.05; G1-SL p < 0.05. Fig. 6B, B1: one-way ANOVA main effect of receptor, Holm-Sidak multiple comparisons B1ΔNT p < 0.05, B1-SL p < 0.01 versus B1).

Stalk-deficient Receptors Exhibit Robust β-Arrestin Association and Ubiquitination, Two Correlates of Enhanced GPCR Activity—To further assess the activity of the stalk-deficient receptors, we employed a β-arrestin2 recruitment assay. β-Arrestin recruitment is a classical hallmark of highly active GPCRs (31). In support of their constitutively-active nature, both B1ΔNT and G1ΔNT have been reported to strongly bind β-arrestin2 whereas their full-length counterparts do not (5, 10). In the present study, we confirmed that B1ΔNT and G1ΔNT robustly co-immunoprecipitate with β-arrestin2, and additionally found that both G1-SL and B1-SL bind β-arrestin2 to a comparably robust extent as the ΔNT mutants (Fig. 7). Multiple iterations of this experiment were quantified and revealed a main effect of receptor transfected with β-arrestin2 relative to β-arrestin2 transfected alone (B1: one-way ANOVA F(2, 6) = 11.58, p = 0.0087, post-hoc: B1 p > 0.05, B1ΔNT p < 0.05, B1-SL p < 0.01; G1: F(2, 6) = 31.93, p = 0.0006, G1 p > 0.05, G1ΔNT p < 0.001, G1-SL p < 0.01). Similar to our reporter assay results shown earlier, G1-SL binding to β-arrestin2 was found to be significantly lower (One-way ANOVA, post-hoc p < 0.05, n = 3) than that of G1ΔNT whereas there was no significant difference between B1ΔNT and B1-SL.

In addition to binding to β-arrestins, highly active GPCRs are often ubiquitinated prior to down-regulation and degradation (32). As with β-arrestin association, B1ΔNT and G1ΔNT have previously been found to be heavily ubiquitinated whereas their full-length counterparts are not (5, 10). As shown in Fig. 8, we found that B1-SL and G1-SL are ubiquitinated to a similar extent as their ΔNT counterparts (B1: one-way ANOVA F(2, 6) = 132.9, p < 0.0001, post-hoc test versus full-length B1, B1ΔNT p < 0.0001, B1-SL p < 0.001; G1 F(2, 6) = 27.50, p = 0.001, G1 p > 0.05, G1ΔNT p < 0.001, G1-SL p < 0.01), which provides further support for the idea that the SL mutants are highly active receptors.

Discussion

Substantial recent progress has been made in understanding the mechanisms of aGPCR activation. These mechanisms are important to understand, given the association of these receptors with several human diseases and the potential value of these receptors as drug targets (1). Specifically, it has been found for a number of aGPCRs that truncation of the receptor N termini up to the point of predicted GAIN domain cleavage leads to increased constitutive activity (5–14). These observations led to the proposal of the disinhibition model of aGPCR activation, which posits that the NTF exerts an inhibitory constraint on signaling by the CTF, with this inhibitory constraint being removed following engagement of the NTF with a large extracellular ligand that results in either dissociation of the

FIGURE 6. G1-SL and B1-SL couple to G proteins. Western blots of co-immunoprecipitation experiments in HEK cells demonstrating that ΔNT and -SL receptors (6A: G1, 6B: B1) robustly associate with Go(13), whereas the full-length versions of the receptors do not. Equal amounts of protein (10–20 μg) were loaded in each lane for the blots shown here, and the results shown are from 3–4 independent experiments (± S.E. shown, *, p < 0.05; **, p < 0.01 versus G1/B1).
NTF from the CTF and/or a conformational change that reduces NTF-mediated inhibition (15). Subsequently, more mechanistically specific variations of the disinhibition model have been proposed, including the cryptic agonist model (7, 9, 11), wherein GAIN domain cleavage and NTF dissociation result in the unveiling of a cryptic agonist peptide on the post-
cleavage stalk of the CTF in a manner analogous to protease-activated receptors (33).

In the studies described above, we tested the cryptic agonist model directly in parallel experiments on two distinct aGPCRs by deleting the stalk regions and broadly assessing receptor activity using a variety of downstream outputs. Our results provide evidence that the stalk region is not a requisite agonist for these two aGPCRs, as we observed that deleting the stalk does not affect signaling to most pathways measured. In the case of ADGRB1/BAI1 (“B1”), removal of the stalk region made no difference whatsoever for any assessment of receptor activity. In fact, we found B1-SL to be significantly more active in the NFAT luciferase assay than B1NT, which suggests that the stalk may actually attenuate the full signaling ability of this receptor. In contrast, studies on ADGRG1/GPR56 (“G1”) resulted in mixed findings, with removal of the stalk region largely abrogating the receptor’s ability to stimulate SRF luciferase but having little effect on the other readouts examined. Additionally, both B1- and G1-SL retained the ability to robustly co-immunoprecipitate with Gα13. Based on these findings, we propose that aGPCRs can mediate both stalk-dependent and stalk-independent signaling, with the relative contribution of the stalk to receptor activity varying substantially between different receptors as well as between different outputs examined.

A recent study by Stoveken et al. (2015) suggested that the NT stalk of G1 is necessary for signaling activity (9). This study reported signaling data from SRE luciferase experiments in transfected cells and GTP loading experiments in a reconstitution system. Our data reported here are in agreement with the findings of Stoveken et al., as we found that the activity of G1-SL was sharply reduced compared with G1∆NT in the SRF luciferase assay, which is very similar to the SRE luciferase assay. However, in other assays in which we assessed G1 activity (TGFα shedding, NFAT luciferase, β-arrestin recruitment and receptor ubiquitination), we found G1-SL to be in an active conformation and capable of mediating receptor signaling to a similar extent as G1∆NT. These results suggest that the stalk region of G1 is necessary for certain aspects of receptor signaling activity but dispensable for others.

There have been prior indications that the cryptic agonist model may represent an incomplete description of aGPCR activation. For example, studies on the Caenorhabditis elegans aGPCR lat-1 demonstrated that mutations blocking cleavage of the receptor’s GAIN domain exerted no effect on the in vivo function of the receptor (34). These in vivo data find a parallel in the in vitro findings reported here regarding the non-cleaving G1-T383A mutant, which we found to exhibit no change in signaling activity relative to wild-type G1. Similarly, a recent report from Peeters et al. demonstrated that non-cleavable versions of GPR64/ADGRG2 can still activate downstream signaling (12). According to the cryptic agonist model, GAIN-mediated cleavage should be essential for exposure of the agonistic peptide sequence on the stalk region. Thus, observations that the activity of at least some aGPCRs is not modulated by GAIN cleavage obviously run counter to this model. Moreover, there is convincing evidence that some aGPCRs do not undergo GAIN-mediated cleavage (35), an observation that needs to be taken into account in general models of aGPCR activation.

Another challenge faced by the cryptic agonist model is the uncertainty surrounding how aGPCR NTF regions become dissociated from their cognate 7TM regions. In the cryptic agonist model, it is envisioned that the N-terminal portion of a cleaved GAIN domain can be released from the receptor’s stalk region in a regulated manner, thereby exposing the agonistic stalk peptide sequence (7, 9, 11). However, the first crystal structures of GAIN domains reported by Arac et al. have cast doubt on whether GAIN domains can actually exist as stable folded protein units in the absence of the hydrophobic stalk peptides (4). Thus, while it is clear that aGPCR NTF regions can become dissociated from their cognate CTF regions (2), it is uncertain whether dissociated GAIN domains leave the stalk behind or take the stalk with them. Interestingly, studies on ADGRL1/latrophilin-1 provided evidence that the release of this receptor NTF region is dependent on two proteolytic steps, with GAIN domain cleavage followed by a second cleavage event that cleaves the receptor’s stalk region to release the GAIN domain and stalk together (36). According to the cryptic agonist model, the resultant 7TM region of such a twice-cleaved aGPCR would be devoid of signaling activity, as the stalk region containing the agonistic peptide would have been lost with the second cleavage event. However, our studies presented here on stalkless versions of G1 and B1 demonstrate that stalkless receptors can still exert significant downstream signaling, albeit signaling that is altered in some cases (as in the case of G1) relative to receptors that possess an intact stalk.

Further work will be needed to elucidate the differences in signaling intermediates that presumably exist between the stalk-dependent versus stalk-independent signaling activities observed in our studies. As shown above, the activation of NFAT luciferase by G1 and B1 was significantly blocked by the Gβγ inhibitor gallein and also blocked to a similar extent by the RGS domain of p115RhoGEF, which would be expected to attenuate signaling by Gα12/13 as well as any Gβγ subunits released from activated Gα12/13. Insofar as the SRF luciferase assay represents a more pure readout of Gα12/13 action, the differential change in activity observed for G1-SL in the SRF versus NFAT luciferase assays may represent a difference in the relative importance of Gα12/13 versus Gβγ-dependent pathways (37). Yet another possibility is that β-arrestins may contribute to G1 and B1 signaling, with the presence of the stalk having little effect on β-arrestin-mediated signaling. Indeed, we found that the ∆NT and SL versions of G1 and B1 both exhibited strong interactions with β-arrestin2. However, the specific contributions of the various G protein subunits and β-arrestins to signaling by G1, B1, and other adhesion GPCRs will require further investigation to truly assess whether the stalk regions might confer bias toward certain receptor-initiated pathways and away from others (38).

Understanding the natural mechanism(s) of aGPCR activation is a critical step toward facilitating drug development efforts aimed at these receptors. For example, the elucidation of agonistic peptide sequences on the N-terminal stalks of certain aGPCRs (7, 9, 11) has provided insights that may lead to the development of peptidomimetic small molecules with agonistic
activity at these receptors. Similarly, the findings reported here that cryptic agonist sequences on aGPCR stalks do not account for the entirety of aGPCR signaling are important because these observations suggest an additional antagonistic effect of tethered GAIN domains on aGPCR activity beyond the simple masking of the stalk region. Therefore, we propose an allosteric antagonist model of aGPCR activation (Fig. 9), in which the NTF can antagonize receptor activity in two distinct ways: (i) by masking the stalk region and (ii) by directly antagonizing the inherent stalk-independent constitutive activity of the 7TM region. The word “allosteric” in this context is meant to convey that the NTF presumably does not block agonist binding in the manner of a competitive antagonist, but rather constrains receptor activity in an allosteric fashion. This model is consistent with the data presented here as well as in previous studies (7, 9, 11) and furthermore is consistent with the possibility that aGPCRs may still signal even if they are not cleaved at the GAIN domain or lose their stalk following GAIN cleavage.

Further insights into the structural determinants of the antagonistic relationship between aGPCR NTF and 7TM regions may help to facilitate discovery of distinct classes of small-molecule aGPCR modulators that either block or potentiate NTF-mediated suppression of aGPCR 7TM signaling. Additionally, a model in which aGPCRs can mediate both stalk-dependent and stalk-independent signaling has clear implications for the future development of biased agonists targeting these receptors (38). In many cases, it is therapeutically desirable to target some but not all pathways downstream of a given receptor. Thus, it will be of interest going forward to study the various members of the aGPCR family on a receptor-by-receptor basis in order to understand the structural determinants of receptor coupling to different downstream signaling pathways to facilitate the discovery of biased ligands possessing therapeutic potential.

Author Contributions—A. K., R. H. P., and R. A. H. designed the experiments and wrote the manuscript. AK performed the experiments focused on ADGRG1 as well as the TGFα shedding assays focused on ADGRB1. R. H. P. and Z. N. T. performed all other experiments focused on ADGRB1. A. K., R. H. P., and R. A. H. analyzed the data and created the figures. All authors made intellectual contributions to the paper and take responsibility for the data.

Acknowledgments—We thank Michelle Giddens (Emory University) for helpful comments about this work and Tohru Kozasa (University of Illinois, Chicago), Keqiang Ye (Emory University) and Shigeki Higashiyama (Ehime University) for kindly providing constructs to facilitate these studies.

References
1. Langenhan, T., Aust, G., and Hamann, J. (2013) Sticky signaling—adhesion class G protein-coupled receptors take the stage. Sci. Signal. 6, re3
2. Hamann, J., Aust, G., Araç, D., Engel, F. B., Formstone, C., Fredriksson, R., Hall, R. A., Harty, B. L., Kirchhoff, C., Knapp, B., Krishnan, A., Liesbcher, I., Lin, H. H., Martinelli, D. C., Monk, K. R., Peeters, M. C., Piao, X., Prömel, S., Schöneberg, T., Schwartz, T. W., Singer, K., Stacey, M., Uszkaryov, Y. A., Vallon, M., Wolfrum, U., Wright, M. W., Xu, L., Langenhan, T., and Schiöth, H. B. (2015) International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors. Pharmacol. Rev. 67, 338–367
3. Prömel, S., Langenhan, T., and Araç, D. (2013) Matching structure with function: the GAIN domain of adhesion-GPCR and PKD1-like proteins. Trends Pharmacol. Sci. 34, 470–478
4. Araç, D., Boucard, A. A., Bolliger, M. F., Nguyen, J., Soltis, S. M., Südhof, T. C., and Brunger, A. T. (2012) A novel evolutionarily conserved domain of cell-adhesion GPCRs mediates autoproteolysis. EMBO J. 31, 1364–1378
5. Stephenson, J. R., Paavola, K. J., Schaefer, S. A., Kaur, B., Van Meir, E. G., and Hall, R. A. (2013) Brain-specific angiogenesis inhibitor-1 signaling, regulation, and enrichment in the postsynaptic density. J. Biol. Chem. 288, 22248–22256
6. Okajima, D., Kudo, G., and Yokota, H. (2010) Brain-specific angiogenesis inhibitor 2 (BAI2) may be activated by proteolytic processing. J. Recept
Role of N-terminal Stalk in aGPCR Activation

Signal Transduct. Res. 30, 143–153
7. Liebscher, I., Schön, J., Petersen, S. C., Fischer, L., Auerbach, N., Demberg, L. M., Mogha, A., Cöster, M., Simon, K. U., Rothemund, S., Monn, K. R., and Schöneberg, T. (2014) A tethered agonist within the ectodomain activates the adhesion G protein-coupled receptors GPR126 and GPR133. Cell Rep. 9, 2018–2026

8. Ward, Y., Lake, R., Yin, J. J., Heger, C. D., Raffeld, M., Goldsmith, P. K., Merino, M., and Kelly, K. (2011) LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. Cancer Res. 71, 7301–7311

9. Stoveken, H. M., Hajduczok, A. G., Xu, L., and Tall, G. G. (2015) Adhesion G protein-coupled receptors are activated by exposure of a cryptic tethered agonist. Proc. Natl. Acad. Sci. U.S.A. 112, 6194–6199

10. Paavola, K. J., Stephenson, J. R., Ritter, S. L., Alter, S. P., and Hall, R. A. (2012) Adhesion G protein-coupled receptor GPR56 controls receptor signaling activity. J. Biol. Chem. 286, 28914–28921

11. Demberg, L. M., Rothemund, S., Schöneberg, T., and Liebscher, I. (2015) Identification of the tethered peptide agonist of the adhesion G protein-coupled receptor GPR64/ADGRG2. Biochim. Biophys. Res. Commun. 464, 743–747

12. Peeters, M. C., Fokkelman, M., Boogaard, B., Egerod, K. L., van de Water, B., Ilzerman, A. P., and Schwartz, T. W. (2015) The adhesion G protein-coupled receptor G2 (ADGRG2/GPR64) constitutively activates SRE and NFkB and is involved in cell adhesion and migration. Cell. Signal. 27, 2579–2588

13. Paavola, K. J., Sidik, H., Zuchero, J. B., Eckart, M., and Talbot, W. S. (2014) Type IV collagen is an activating ligand for the adhesion G protein-coupled receptor GPR126. Sci. Signal. 7, ra76

14. Hu, Q. X., Dong, J. H., Hu, H. B., Zhang, D. L., Ren, H. Z., Ma, M. L., Cai, Y., Zhao, T. C., Yin, X. L., Yu, X., Xue, T., Xu, Z. G., and Sun, J. P. (2014) Constitutive Gia coupling activity of very large G protein-coupled receptor 1 (VLGR1) and its regulation by PDZD7 protein. J. Biol. Chem. 289, 24215–24225

15. Paavola, K. J., and Hall, R. A. (2012) Adhesion G protein-coupled receptors: signaling, pharmacology, and mechanisms of activation. Mol. Pharmacol. 82, 777–783

16. Piao, X., Hill, R. S., Bodell, A., Chang, B. S., Basel-Vanagaite, L., Straussberg, R., Dobyns, W. B., Qasrawi, B., Winter, R. M., Innes, A. M., Voit, T., Ross, M. E., Michaud, J. L., Descarce, J. C., Barkovich, A. J., and Walsh, C. A. (2004) G protein-coupled receptor-dependent development of human frontal cortex. Science 303, 2033–2036

17. Park, D., Tosello-Trampont, A. C., Elliott, M. R., Lu, M., Haney, L. B., Ma, J. G., Bollag, G., and Sternweis, P. C. (1998) p115 RhoGEF, a GTPase activating protein for Gα13, inhibits neutrophil chemotaxis and inflammation. Mol. Pharmacol. 54, 410–418

18. Hochreiter-Hufford, A. E., Lee, C. S., Kinchen, J. M., Sokolowski, J. D., and Smrcka, A. V. (2006) β-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 17, 159–165

19. Marchese, A., and Trejo, J. (2013) Ubiquitin-dependent regulation of G protein-coupled receptor trafficking and signaling. Cell. Signal. 25, 707–716

20. Coughlin, S. R. (2000) Thrombin signalling and protease-activated receptors. Nature 407, 258–264

21. Prömel, S., Frickenhaus, M., Hughes, S., Mestek, L., Staunton, D., Woolcock, A. G., Neubert, T. A., and Petrenko, A. G. (2009) Dissociation of the subunits of the calcium-independent receptor of TGFβ/H9260. J. Biol. Chem. 284, 6194–6199

22. Smrcka, A. V. (2008) G protein-coupled receptor (GPCR) signaling: amino- and carboxyl-terminal domains as new promoters of myoblast fusion. J. Biol. Chem. 283, 14469–14478

23. Smrcka, A. V. (2008) Calcium-dependent regulation of G protein-coupled receptor 56 promotes myoblast fusion through serum response factor- and nuclear factor of activated T cell-mediated signalling but is not essential for muscle development in vivo. FEBS J. 280, 6097–6113

24. Coughlin, S. R. (2000) Thrombin signalling and protease-activated receptors. Nature 407, 258–264

25. Prömel, S., Frickenhaus, M., Hughes, S., Mestek, L., Staunton, D., Woolcock, A. G., Neubert, T. A., and Petrenko, A. G. (2009) Dissociation of the subunits of the calcium-independent receptor of TGFβ/H9260. J. Biol. Chem. 284, 6194–6199

26. Smrcka, A. V. (2008) G protein-coupled receptor (GPCR) signaling: amino- and carboxyl-terminal domains as new promoters of myoblast fusion. J. Biol. Chem. 283, 14469–14478

27. Smrcka, A. V. (2008) G protein-coupled receptor (GPCR) signaling: amino- and carboxyl-terminal domains as new promoters of myoblast fusion. J. Biol. Chem. 283, 14469–14478